• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Exact Sciences Earns 2025 Great Place To Work® Certification™

    5/12/25 10:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care
    Get the next $EXAS alert in real time by email

    Award marks seventh consecutive year company has received prestigious distinction

    Exact Sciences (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany.

    The recognition is based on a confidential survey of employees around the world, offering an independent assessment of Exact Sciences' culture, work environment, and leadership. This year, 77% of employees called Exact Sciences a Great Place To Work – 20 points higher than the average U.S.-based company. Great Place To Work is the global authority on workplace culture, employee experience, and leadership behaviors proven to deliver market-leading revenue, employee retention, and increased innovation.

    "Exact Sciences is proud to be recognized as a Great Place To Work for the seventh year in a row—an honor that reflects the passion, integrity, and drive for innovation of our incredible team," said Sarah Condella, executive vice president of human resources at Exact Sciences. "Our purpose of eradicating cancer guides everything we do, and we're committed to creating a workplace where everyone feels respected, included, and empowered."

    By achieving this distinction, Exact Sciences joins an elite group of organizations that have demonstrated exceptional workplace practices, a willingness to act on employee feedback, and a strong commitment to employee well-being. The anonymous feedback collected during certification focuses on factors known to impact the quality of an employee's experience, such as trust, pride, respect, and camaraderie.

    "Great Place To Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience," says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work. She emphasizes that Certification is the sole official recognition earned by the real-time feedback of employees regarding their company culture. "By successfully earning this recognition, it is evident that Exact Sciences stands out as one of the top companies to work for, providing a great workplace environment for its employees."

    According to Great Place To Work research, job seekers are 4.5 times more likely to find a great boss at a certified great workplace and 15 times more likely to choose to work at a certified great workplace. Additionally, employees at certified workplaces are 93% more likely to look forward to coming to work and are twice as likely to be paid fairly, to earn a fair share of the company's profits, and to have a fair chance at promotion.

    Exact Sciences is looking for talented people who are passionate about fighting cancer. For more information and to view a complete list of job openings, visit the company careers site.

    About Exact Sciences Corp.

    A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

    NOTE: Exact Sciences and Cologuard are trademarks of Exact Sciences Corporation. Oncotype is a trademark of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences.

    About Great Place To Work® Certification™

    Great Place To Work® Certification™ is the most definitive "employer-of-choice" recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified.

    About Great Place To Work®

    As the global authority on workplace culture, Great Place To Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List. Learn more at greatplacetowork.com and follow Great Place To Work on LinkedIn, Twitter, Facebook and Instagram.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250512833110/en/

    Media Contact (U.S.):

    Blair Brophy

    +1 608-630-7391

    [email protected]



    Investor Contact:

    Derek Leckow

    608-893-0009

    [email protected]

    Get the next $EXAS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXAS

    DatePrice TargetRatingAnalyst
    1/20/2026$105.00Outperform → Neutral
    Mizuho
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    4/10/2025$60.00Outperform
    Mizuho
    3/13/2025$52.00Sector Perform
    RBC Capital Mkts
    1/23/2025$70.00Overweight
    Barclays
    8/28/2024$75.00Overweight
    Wells Fargo
    6/27/2024$70.00Sector Outperform
    Scotiabank
    6/3/2024$75.00Buy
    Jefferies
    More analyst ratings

    $EXAS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests

    Passage of MCED legislation marks major milestone for early cancer detection Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection (MCED) tests. Nearly 70% of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening,1,2 and cancer remains the second leading cause of death in the U.S.1 By aligning public policy with scientific innovation and patient need, this legislation represents a critical step toward addressing that unmet need and expanding access to this emerging

    2/3/26 2:32:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

    Milestone underscores test's significant role as a global standard-of-care in guiding personalized breast cancer treatment The predictive utility of this test helped an estimated 1.6 million patients safely avoid potentially unnecessary chemotherapy Economic models demonstrate improved outcomes and the potential for U.S. system-wide cost savings Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score® test: more than two million breast cancer patients worldwide have now used the test to help guide treatment decisions. Backed by more than two decades of

    2/3/26 9:03:00 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $EXAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exact Sciences downgraded by Mizuho with a new price target

    Mizuho downgraded Exact Sciences from Outperform to Neutral and set a new price target of $105.00

    1/20/26 9:08:04 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Exact Sciences from Outperform to In-line and set a new price target of $105.00

    1/5/26 8:47:19 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Mizuho initiated coverage on Exact Sciences with a new price target

    Mizuho initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $60.00

    4/10/25 12:41:36 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    1/30/26 4:01:09 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    1/23/26 6:03:01 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form DEFM14A filed by Exact Sciences Corporation

    DEFM14A - EXACT SCIENCES CORP (0001124140) (Filer)

    1/9/26 8:15:20 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/13/24 12:56:28 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, GM, Screening Orville Jacob A converted options into 73,080 shares, covered exercise/tax liability with 68,437 shares and was granted 72,523 shares, increasing direct ownership by 332% to 100,403 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    12/30/25 4:30:14 PM ET
    $EXAS
    Medical Specialities
    Health Care

    EVP, GM, Precision Oncology Baranick Brian converted options into 73,080 shares, covered exercise/tax liability with 84,097 shares and was granted 92,523 shares, increasing direct ownership by 364% to 103,874 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    12/30/25 4:30:12 PM ET
    $EXAS
    Medical Specialities
    Health Care

    EVP, Human Resources Condella Sarah converted options into 47,208 shares, covered exercise/tax liability with 41,938 shares and was granted 42,018 shares, increasing direct ownership by 58% to 129,134 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    12/30/25 4:30:09 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

    SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

    3/19/25 4:10:00 PM ET
    $EXAS
    $QTRX
    $SERA
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EXAS
    Financials

    Live finance-specific insights

    View All

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Exact Sciences Announces Third Quarter 2025 Results

    Reports record revenue, raises full-year guidance, generates record cash from operations Third quarter and recent highlights Delivered record total third quarter revenue of $851 million, an increase of 20% on a reported and core revenue basis, including Screening revenue of $666 million and Precision Oncology revenue of $184 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $78 million and $10 million, respectively Generated record cash from operations and free cash flow Launched Cancerguard®, the company's multi-cancer early detection test, for patients in the United States Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer scree

    11/3/25 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences Schedules Third Quarter 2025 Earnings Call

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2025 financial results after the close of the U.S. financial markets on November 3, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2025 webcast & conference call details Date: Monday, November 3, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers

    10/8/25 7:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    11/13/24 2:58:53 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Exact Sciences Corporation

    SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

    11/8/24 10:52:39 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    10/7/24 11:37:08 AM ET
    $EXAS
    Medical Specialities
    Health Care